BOSTON, June 22, 2024 (GLOBE NEWSWIRE) -- Novotech, a global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to expedite the development of cutting-edge therapeutics across all phases, has today published a leading industry report, Liver Cancer - Global Clinical Trial Landscape. Liver cancer is the sixth most diagnosed cancer worldwide and the third-most common cause of cancer-related deaths.
The report highlights the ongoing investment into liver cancer research globally and the significant treatment innovations that are designed to improve outcomes for patients.
The Novotech research analyst team provides these expert reports monthly, completely free of charge. These reports offer up-to-date insights into global clinical trial activity, revealing regions that experience the highest trial volumes and the factors behind these trends. They tackle the hurdles biotech firms face in specific therapeutic areas and discuss future paths in therapy and investment trends.
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer, accounting for approximately 90% of all cases. HCC typically arises in individuals with chronic liver conditions such as hepatitis virus infection, cirrhosis, certain inherited liver diseases, or exposure to aflatoxins and affects men more than women.
The Liver Cancer - Global Clinical Trial Landscape report finds that Asia had the highest incidence, contributing approximately 600,000 cases, which represented over 70% of the global burden. Within Asia, China alone reported more than 360,000 cases. Europe reported about 88,000 cases, while Africa faced significant challenges with 73,000 cases. North America saw over 48,000 cases, predominantly from the United States.
The Novotech report shows there’s a robust clinical trial pipeline for liver cancer, with over 1,700 trials initiated since 2018. Asia-Pacific and North America are at the forefront, contributing 55% and 24% respectively, followed by Europe at 16% and ROW at 5%, with Mainland China, South Korea, Spain and the United States emerging as top destinations for conducting trials.
These trials are across all phases, with a significant focus on early and mid-phase trials in Asia-Pacific and North America (Phase I and II), compared to Europe and the ROW which showed a lower overall number of trials. This data could suggest a difference in regional approaches to clinical research, possibly influenced by factors like funding, regulatory environments, and infrastructure.
Ongoing trials dominate globally, with Asia-Pacific leading again in ongoing and completed studies. North America and Europe closely follow, showing considerable activity in ongoing trials but fewer completed ones.
The treatment landscape for HCC is diverse and evolving. While surgical resection and liver transplantation offer the best long-term survival, many patients are unsuitable due to tumor size or liver conditions. Other treatments include traditional chemotherapy, targeted therapies like monoclonal antibodies and small molecules, and immunotherapies such as immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs). First-line treatments often combine atezolizumab and bevacizumab, while second-line options include lenvatinib, sorafenib, regorafenib, and cabozantinib.
Key takeaways from the report are:
- The drug development landscape includes approximately 70 drugs in preclinical stages, 23 in research, 51 in Phase I, 37 in Phase I/II, 66 in Phase II, 17 in Phase III, and 23 marketed drugs.
- Due to its large population and lower volume of studies, the Asia-Pacific region has lower competing trial risk with a trial density 4 times lower than that of the US and about 2 times lower than Europe.
- The funding landscape for liver cancer research shows substantial support, particularly through public and venture capital funding. The United States ($4,898 million) and China ($3,131 million) have seen significant venture capital investments in liver cancer research between 2019 and 2023.
- Funding predominantly supports preclinical, Phase I, and Phase II stages, with lesser amounts for discovery, Phase III, IND/CTA filed, and marketed stages.
- A SWOT analysis reveals strengths in multidisciplinary approaches and evolving therapies, but also highlights weaknesses like side effects and limited access to advanced treatments. Opportunities lie in precision medicine and immunotherapy, while threats include rising healthcare costs and insufficient funding for research.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3310a56-88d7-4e4a-a0f5-8cc9bd2779ae
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
-
【东方美学,世界共享】徐结根老师作品将在法国卢浮宫展出2024年7月6日-20日,“新生万物——中国非遗与当代设计展”将于卢浮宫西翼的法国设计类展览最高殿堂——法国装饰艺术博物馆举行。徐结根老师获邀携作品《听观照》2024-06-24
-
亚洲出版业协会宣布「2024 年度卓越新闻奖」获奖名单《纽约时报》执行主编Joseph Kahn谈论两极化时代新闻报道的关键作用 香港 - Media OutReach Newswire - 2024年6月21日 - 致力于表扬杰出新闻工作、其总部位于2024-06-24
-
金百泽中试+1 3C电子PCB柔性贴装验证线揭牌投产6月20日,以“工业互联 智造湾区”为主题的“2024智造湾区论坛暨深圳市工赋数字化促进中心揭牌仪式”在深圳宝安大铲湾盛大举行,本次活动由深圳国家高技术2024-06-24
-
Novotech Liver Cancer Research Landscape Report Finds 1,700 Trials Initiated GloballyBOSTON, June 22, 2024 (GLOBE NEWSWIRE) -- Novotech, a global full-service clinical Contract Research Organization (CRO) specializing in partnerin2024-06-24
-
以赛促情 赣台大学生排球邀请赛“秀”出两岸风采2024年6月18日至24日,纪念郑成功诞辰400周年赣台大学生排球邀请赛举办。活动邀请中华台北运动总会主席吕威震、副主席刘家增、秘书长陈芊妤,台北市政府市政顾问2024-06-24